— Research note —
GHRP-6
First-generation hexapeptide ghrelin receptor agonist that helped establish the synthetic secretagogue receptor pharmacology field.
GHRP-6 (growth hormone-releasing peptide-6) is a synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) developed by Cyril Bowers and colleagues at Tulane University in the 1980s. The molecule was among the earliest synthetic growth hormone secretagogues characterized and played a pivotal role in establishing the existence of a distinct, non-GHRH receptor mediating growth hormone release. The pharmacology of GHRP-6 and related early GHRPs ultimately led to the identification of the orphan receptor GHSR and, in 1999, to the discovery of its endogenous ligand ghrelin.
In comparative GHRP studies, GHRP-6 is notable for producing pronounced appetite stimulation alongside growth hormone release, a profile that reflects activation of hypothalamic ghrelin receptors and prefigured the central role of the ghrelin system in energy balance regulation. The peptide also produces modest elevations in cortisol and prolactin at growth-hormone-active doses, a profile intermediate between the more selective ipamorelin and the more broadly active GHRP-2.
The compound has been used extensively as a research tool for studies of growth hormone secretion dynamics, combination pharmacology with GHRH analogs, and the central regulation of appetite by the ghrelin system. Its historical importance in the discovery of the ghrelin receptor and the appetite-stimulating actions of synthetic ghrelin receptor agonists have made GHRP-6 a frequently cited reference compound in pituitary and metabolic pharmacology.
GHRP-6 is supplied here for laboratory research use only and is not intended for human consumption. Researchers continue to use the compound in mechanistic studies of GHSR-1a signaling, appetite regulation, and comparative GHRP pharmacology.
Mechanism
GHRP-6 binds the growth hormone secretagogue receptor type 1a (GHSR-1a) on pituitary somatotrophs and on hypothalamic arcuate nucleus neurons, including NPY/AgRP-expressing cells implicated in appetite regulation. Receptor activation couples through Gq to phospholipase C, mobilizing intracellular calcium and stimulating growth hormone exocytosis from somatotrophs while activating central feeding circuits in the hypothalamus.
The hexapeptide produces a characteristic profile of growth hormone release, modest cortisol and prolactin elevation, and pronounced acute appetite stimulation. The appetite-stimulating activity reflects engagement of central GHSR-1a expressed on NPY/AgRP neurons, with downstream activation of orexigenic neuropeptide systems. Combination of GHRP-6 with GHRH analogs produces synergistic growth hormone release reflecting the dual-receptor regulation of somatotrophs, with Gs-mediated cAMP signaling (from GHRH receptor) and Gq-mediated calcium signaling (from GHSR-1a) acting in complementary fashion.
Research history
Cyril Bowers and colleagues at Tulane University identified the GHRP scaffold in the 1980s through structure-activity exploration of met-enkephalin analogs that retained growth hormone-releasing activity in pituitary cell preparations. GHRP-6 emerged as a representative early member of the class with characterized pharmacology.
The molecule was subsequently used as a tool compound by Merck Research Laboratories during their development of orally bioavailable secretagogues, work that culminated in the cloning of the GHSR receptor by the Smith and Howard groups in 1996. The discovery of the endogenous ligand ghrelin by Kojima and colleagues in 1999 completed the receptor-ligand pair and validated the GHRPs as synthetic agonists of a physiologically important system.
Subsequent research has used GHRP-6 extensively in combination pharmacology studies with GHRH analogs, in mechanistic characterization of central ghrelin receptor signaling, and in models of appetite regulation. The compound remains in research-chemical catalogs as a historically important reference compound for the secretagogue field, frequently cited in reviews of ghrelin biology and synthetic GHRP pharmacology.
References
- Bowers CY, et al. 1984. Structure-activity relationships of a synthetic pentapeptide that specifically releases growth hormone in vitro. Endocrinology. PMID: 6692581
- Howard AD, et al. 1996. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. PMID: 8688086
- Kojima M, et al. 1999. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. PMID: 10604470
- Smith RG, et al. 1997. Peptidomimetic regulation of growth hormone secretion. Endocr Rev. PMID: 9408744
- Tschop M, et al. 2000. Ghrelin induces adiposity in rodents. Nature. PMID: 11057670
- Smith RG. 2005. Development of growth hormone secretagogues. Endocr Rev. PMID: 15814848
Do you have any questions about GHRP-6?
Pick a path. The research assistant has the full literature context loaded.
Information presented in third-person scientific context. Research use only. Not medical advice; not for human consumption.